Onkos Surgical has opened its new NanoCept Innovation Center facility in Bridgewater Township, N.J.

The new 4,600-square-foot facility is located in the New Jersey Center of Excellence. Onkos will now have a full innovation process in-house for its flagship NanoCept antibacterial technology, which is touted as the first-ever orthopedic antibacterial coating sold in the U.S. market.

The product provides a proactive approach against intraoperative bacterial contamination to advance the field of orthopedic implants. This production capacity expansion lets the company meet the growing demand for NanoCept technology from surgeons and hospitals.

“Onkos is proud to have worked with the FDA to bring to market the first antibacterial coating technology. The opening of the NanoCept Innovation Center marks another important milestone in our company’s journey,” said Patrick Treacy, Onkos Surgical’s founder and CEO. “This investment will allow us to get this groundbreaking technology into the hands of more surgeons, faster, and it puts us in a position to help more patients with complex orthopedic conditions.”

The NanoCept Innovation Center will employ a team of chemists, engineers, and technicians in the new facility to lead innovation operations. Onkos’ headquarters are located at 77 East Halsey Road in Parsippany, N.J.

“The opening of the NanoCept Innovation Center in Bridgewater exemplifies the cutting-edge innovation that defines New Jersey’s 7th Congressional District,” said Congressman Tom Kean, Jr. “Advancements like those being pursued by Onkos Surgical have the potential to drive meaningful progress in patient care and expand possibilities in modern medicine. Congratulations to Onkos on this remarkable milestone.”

In October, the company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Eleos proximal tibia with NanoCept antibacterial technology.